Reimbursed Care Access in Guinea-Bissau

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Guinea‑Bissau is a party to the 1971 UN Convention on Psychotropic Substances which requires national controls that cover serotonergic psychedelics such as psilocybin #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is controlled under international psychotropic substances controls to which Guinea‑Bissau is a party #.

No public evidence of an authorized, reimbursed esketamine (Spravato) program or marketing authorization in Guinea‑Bissau; esketamine as a branded intranasal treatment for treatment‑resistant depression is typically available only where a national regulator has approved and where certified treatment settings and reimbursement frameworks exist. Globally, esketamine is distributed under tightly controlled REMS‑style programs and is marketed in countries after national regulatory approval (for example, FDA approval in the United States) rather than through informal importation #. In Guinea‑Bissau there are no publicly available regulatory listings or reimbursement schemes indicating routine clinical access to esketamine; access would therefore be limited to authorised clinical research or individual import/compassionate‑use arrangements if they were arranged with competent authorities (none publicly documented).

Ketamine is recognized internationally as an essential medicine for anaesthesia and procedural sedation and is routinely used in low‑resource and emergency settings because of its safety profile and parenteral routes of administration; it appears on the WHO Model List of Essential Medicines, supporting its routine medical availability worldwide including in many low‑ and middle‑income countries #.

Regulatory/medical context: Guinea‑Bissau is a contracting party to the relevant UN conventions that require control and medical regulation of anaesthetics and psychotropic substances; national implementation means ketamine is regulated for medical use rather than available for recreational use #. In practice, ketamine is most commonly supplied and used in hospitals and surgical/obstetric settings as an injectable anaesthetic. There is no publicly documented national reimbursement program in Guinea‑Bissau for ketamine when used in novel psychiatric indications (e.g., repeated ketamine infusions for TRD), and no evidence of a national medicines‑benefit scheme that covers psychedelic‑assisted psychiatric protocols. Any use of ketamine for psychiatric indications in Guinea‑Bissau would therefore likely be off‑label, arranged privately or within a clinical/research setting, and not part of a structured, reimbursed national mental‑health program. The WHO listing supports clinical availability for anaesthesia but not reimbursement for psychedelic‑assisted therapy in the absence of a national program #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and related tryptamines are covered by the international psychotropic substances framework to which Guinea‑Bissau is party #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT falls within the class of controlled tryptamine derivatives subject to national controls in countries that implement the 1971 Convention, including Guinea‑Bissau #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of routine medical care in Guinea‑Bissau and would be controlled under national narcotics/psychotropic legislation consistent with UN treaty obligations #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although ayahuasca is a traditional botanical preparation containing DMT, its active components are controlled under international and national psychotropic drug controls; there is no documented legal framework in Guinea‑Bissau authorizing ritual or medical ayahuasca use. Guinea‑Bissau’s obligations under the 1971 Convention support national controls of the DMT component #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (a phenethylamine hallucinogen) is controlled under international psychotropic frameworks and is not known to have authorized medical programs or reimbursement in Guinea‑Bissau #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C‑series phenethylamines are controlled under most national implementations of the 1971 Convention and are not authorized for medical use in Guinea‑Bissau outside formal research settings #.